SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MIDDLETON FRED A

(Last)

(First)

(Middle)

400 S. EL CAMINO REAL, SUITE 1200

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDOCYTE INC [ ECYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2011

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/09/2011		C		880,831	A	⁽¹⁾	1,017,304⁽²⁾	I	By Sanderling Venture Partners V, L.P.⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		435,861	A	⁽¹⁾	435,861	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		267,491	A	⁽¹⁾	267,491	I	By Sanderling Venture Partners V Co-Investment Fund, L.P.⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		215,719	A	⁽¹⁾	249,148⁽⁵⁾	I	By Sanderling V Biomedical, L.P.⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		162,170	A	⁽¹⁾	162,170	I	By Sanderling V Biomedical Co-Investment Fund, L.P.⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		99,791	A	⁽¹⁾	113,315⁽⁶⁾	I	By Sanderling V Limited Partnership⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		17,318	A	⁽¹⁾	149,003⁽⁷⁾	I	By Sanderling Ventures Management V⁽³⁾⁽⁸⁾
Common Stock	02/09/2011		C		88,794	A	⁽¹⁾	100,828⁽⁹⁾	I	By Sanderling V Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		30,766	A	⁽¹⁾	30,766	I	By Sanderling Ventures Management VI⁽³⁾⁽⁸⁾
Common Stock	02/09/2011		C		10,049	A	⁽¹⁾	10,049	I	By Sanderling VI Limited Partnership⁽³⁾⁽⁴⁾
Common Stock	02/09/2011		C		8,434	A	⁽¹⁾	8,434	I	By Sanderling VI Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Common Stock								785,417	I	By Sanderling V Strategic Exit Fund, L.P.⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series B Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			255,458	⁽¹⁾	⁽¹⁾	Common Stock	255,458	⁽¹⁾	0	I	By Sanderling Venture Partners V, L.P.⁽³⁾⁽⁴⁾
Series C-1 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			255,458	⁽¹⁾	⁽¹⁾	Common Stock	255,458	⁽¹⁾	0	I	By Sanderling Venture Partners V, L.P.⁽³⁾⁽⁴⁾
Series C-2 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			340,612	⁽¹⁾	⁽¹⁾	Common Stock	340,612	⁽¹⁾	0	I	By Sanderling Venture Partners V, L.P.⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			29,303	⁽¹⁾	⁽¹⁾	Common Stock	29,303	⁽¹⁾	0	I	By Sanderling Venture Partners V, L.P.⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			435,861	⁽¹⁾	⁽¹⁾	Common Stock	435,861	⁽¹⁾	0	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			267,491	⁽¹⁾	⁽¹⁾	Common Stock	267,491	⁽¹⁾	0	I	By Sanderling Venture Partners V Co-Investment Fund, L.P.⁽³⁾⁽⁴⁾
Series B Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			62,574	⁽¹⁾	⁽¹⁾	Common Stock	62,574	⁽¹⁾	0	I	By Sanderling V Biomedical, L.P.⁽³⁾⁽⁴⁾
Series C-1 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			62,573	⁽¹⁾	⁽¹⁾	Common Stock	62,573	⁽¹⁾	0	I	By Sanderling V Biomedical, L.P.⁽³⁾⁽⁴⁾
Series C-2 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			83,431	⁽¹⁾	⁽¹⁾	Common Stock	83,431	⁽¹⁾	0	I	By Sanderling V Biomedical, L.P.⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			7,141	⁽¹⁾	⁽¹⁾	Common Stock	7,141	⁽¹⁾	0	I	By Sanderling V Biomedical, L.P.⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			162,170	⁽¹⁾	⁽¹⁾	Common Stock	162,170	⁽¹⁾	0	I	By Sanderling V Biomedical Co-Investment Fund, L.P.⁽³⁾⁽⁴⁾
Series B Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			25,316	⁽¹⁾	⁽¹⁾	Common Stock	25,316	⁽¹⁾	0	I	By Sanderling V Limited Partnership⁽³⁾⁽⁴⁾
Series C-1 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			25,315	⁽¹⁾	⁽¹⁾	Common Stock	25,315	⁽¹⁾	0	I	By Sanderling V Limited Partnership⁽³⁾⁽⁴⁾
Series C-2 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			33,755	⁽¹⁾	⁽¹⁾	Common Stock	33,755	⁽¹⁾	0	I	By Sanderling V Limited Partnership⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			15,405	⁽¹⁾	⁽¹⁾	Common Stock	15,405	⁽¹⁾	0	I	By Sanderling V Limited Partnership⁽³⁾⁽⁴⁾
Series B Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			3,695	⁽¹⁾	⁽¹⁾	Common Stock	3,695	⁽¹⁾	0	I	By Sanderling Ventures Management V⁽³⁾⁽⁸⁾
Series C-1 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			3,695	⁽¹⁾	⁽¹⁾	Common Stock	3,695	⁽¹⁾	0	I	By Sanderling Ventures Management V⁽³⁾⁽⁸⁾
Series C-2 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			4,927	⁽¹⁾	⁽¹⁾	Common Stock	4,927	⁽¹⁾	0	I	By Sanderling Ventures Management V⁽³⁾⁽⁸⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			5,001	⁽¹⁾	⁽¹⁾	Common Stock	5,001	⁽¹⁾	0	I	By Sanderling Ventures Management V⁽³⁾⁽⁸⁾
Series B Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			22,526	⁽¹⁾	⁽¹⁾	Common Stock	22,526	⁽¹⁾	0	I	By Sanderling V Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Series C-1 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			22,526	⁽¹⁾	⁽¹⁾	Common Stock	22,526	⁽¹⁾	0	I	By Sanderling V Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Series C-2 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			30,035	⁽¹⁾	⁽¹⁾	Common Stock	30,035	⁽¹⁾	0	I	By Sanderling V Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			13,707	⁽¹⁾	⁽¹⁾	Common Stock	13,707	⁽¹⁾	0	I	By Sanderling V Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			30,766	⁽¹⁾	⁽¹⁾	Common Stock	30,766	⁽¹⁾	0	I	By Sanderling Ventures Management VI⁽³⁾⁽⁸⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			10,049	⁽¹⁾	⁽¹⁾	Common Stock	10,049	⁽¹⁾	0	I	By Sanderling VI Limited Partnership⁽³⁾⁽⁴⁾
Series C-3 Convertible Preferred Stock	⁽¹⁾	02/09/2011		C			8,434	⁽¹⁾	⁽¹⁾	Common Stock	8,434	⁽¹⁾	0	I	By Sanderling VI Beteiligungs GmbH & Co. KG⁽³⁾⁽⁴⁾
Stock Option (right to buy)	$7.23	02/09/2011		A		15,706		⁽¹⁰⁾	02/09/2021	Common Stock	15,706	$0.00	15,706	D

Explanation of Responses:

1. Each share of the Issuer's Series A-1, Series A-2, Series B, Series C-1, Series C-2 and Series C-3 Preferred Stock automatically converted into shares of Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.

2. 72,502 shares held by Sanderling Venture Partners V, L.P. are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.

3. Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.

4. Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling VI Limited Partnership and Sanderling V Strategic Exit Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling V Strategic Exit Fund, L.P. and Sanderling VI Limited Partnership.

5. 17,759 shares held by Sanderling V Biomedical, L.P. are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.

6. 7,185 shares held by Sanderling V Limited Partnership are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.

7. 44,502 shares held by Sanderling Ventures Management V are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.

8. Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership.

9. 6,393 shares held by Sanderling V Beteiligungs GmbH & Co. KG are subject to repurchase based on milestones set forth in the Restricted Stock Purchase Agreement dated July 10, 2001 between the Company and each of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., ABV Holding Company 7 LLC, Douglas G. Bailey, and Cincinnati Financial Corporation.

10. Shares subject to the option vest 1/3 of the shares upon the business day before each of the Issuer's first three annual stockholder meetings following February 9, 2011.

Remarks:

	/s/ Fred A. Middleton	02/11/2011
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.